Between 5-10% of all cancers, including those of the breast, ovary, uterus, prostate, and gastrointestinal system can be accounted for by hereditary cancers.1

Genetic testing plays a crucial role in identifying individuals who have inherited variants within cancer susceptibility genes and are at increased risk of developing hereditary cancer. This information is invaluable for guiding screening, personalized treatment and preventive strategies aimed at improving the survival and outcomes for individuals.

Multi-gene next generation sequencing (NGS) panels have emerged as a widely accepted and clinically viable option for the diagnosis of heritable cancers. However, many targeted NGS panels struggle to identify key hereditary cancer CNVs and require additional multiplex ligation dependent probe amplification (MLPA) analysis to detect them, limiting their usefulness in testing.

With its complete scope, including the detection of single nucleotide variants (SNVs), insertions and deletions (INDELs) and a wide range of copy number variants (CNVs), GALEAS HereditaryPlus combines an innovative NGS panel with optimized bioinformatics to offer a viable option for reducing costly and time consuming MLPA and ensure unparalleled precision in hereditary cancer testing.

GALEAS HereditaryPlus is an innovative NGS panel that includes a meticulously curated collection of 146 genes well-established in their associations with hereditary cancer. The targeted gene list addresses not only key cancer syndromes like Lynch Syndrome but also covers rarer hereditary cancer types like Phaeochromocytoma and pediatric cancers like Wilms tumor, ensuring a comprehensive understanding of the genetic landscape. The ability to target many types of cancer in one assay enables laboratories to streamline hereditary testing workflows.

Table 1: Recommended genes for inclusion.